LCL-161

DB12085InvestigationalSmall molecule

LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.

Chemical structure of LCL-161
Formula / weight
C26H33FN4O3S · 500.63 g/mol (avg)
Code names
LCL 161

Resolves to

Compound
UNII6TNS415Y3PCAS1005342-46-0ChEMBLCHEMBL2431768PubChem24737642
Structure
InChIKeyUFPFGVNKHCLJJO-SSKFGXFMSA-NSMILESCN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C1=NC(=CS1)C(=O)C1=CC=C(F)C=C1
Targets
O15392BIRC5Q96CA5BIRC7Q13075NAIPQ13489BIRC3Q13490BIRC2P98170XIAP

What you can answer from here — as of January 29, 2025

6Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
39Drug interactionsStructured to mechanism, not free text
Sign in
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with LCL-161, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In